295 related articles for article (PubMed ID: 33229935)
1. Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia.
Schimmenti C; Sucato V; Manzone E; Cancellieri G; Mortillaro F; Novo G; Galassi AR; Venturella F
Coron Artery Dis; 2021 Jun; 32(4):340-344. PubMed ID: 33229935
[TBL] [Abstract][Full Text] [Related]
2. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
4. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
[TBL] [Abstract][Full Text] [Related]
5. Evaluating bempedoic acid for the treatment of hyperlipidaemia.
Penson P; McGowan M; Banach M
Expert Opin Investig Drugs; 2017 Feb; 26(2):251-259. PubMed ID: 28064554
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
7. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
[TBL] [Abstract][Full Text] [Related]
8. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
9. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
10. Bempedoic Acid: A New Drug for an Old Problem.
Nguyen D; Du N; Sulaica EM; Wanat MA
Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
[TBL] [Abstract][Full Text] [Related]
11. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
Nguyen H; Akamnonu I; Yang T
Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
[TBL] [Abstract][Full Text] [Related]
12. Role of Bempedoic Acid in Clinical Practice.
Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
[TBL] [Abstract][Full Text] [Related]
13. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
Agarwala A; Quispe R; Goldberg AC; Michos ED
Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
[TBL] [Abstract][Full Text] [Related]
14. Role of Bempedoic Acid in Dyslipidemia Management.
Kelly MS; Sulaica EM; Beavers CJ
J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
[TBL] [Abstract][Full Text] [Related]
15. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Powell J; Piszczatoski C
Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
17. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Brandts J; Ray KK
Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
[TBL] [Abstract][Full Text] [Related]
18. Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis.
Masson W; Lobo M; Lavalle-Cobo A; Molinero G
Clin Investig Arterioscler; 2021; 33(3):117-126. PubMed ID: 33328138
[TBL] [Abstract][Full Text] [Related]
19. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.
Zagelbaum NK; Yandrapalli S; Nabors C; Frishman WH
Cardiol Rev; 2019; 27(1):49-56. PubMed ID: 29939848
[TBL] [Abstract][Full Text] [Related]
20. Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.
Tummala R; Gupta M; Devanabanda AR; Bandyopadhyay D; Aronow WS; Ray KK; Mamas M; Ghosh RK
Ann Med; 2022 Dec; 54(1):1287-1296. PubMed ID: 35533049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
